Moderna (MRNA)
(Real Time Quote from BATS)
$57.44 USD
+0.13 (0.23%)
Updated Oct 16, 2024 03:43 PM ET
After-Market: $57.45 +0.01 (0.02%) 4:08 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.44 USD
+0.13 (0.23%)
Updated Oct 16, 2024 03:43 PM ET
After-Market: $57.45 +0.01 (0.02%) 4:08 PM ET
4-Sell of 5 4
F Value B Growth D Momentum F VGM
Zacks News
Pfizer (PFE), BioNTech Seek Full Approval for COVID Jab Booster
by Zacks Equity Research
The booster dose of Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty dose induced significant SARS-CoV-2 neutralizing antibody titers in phase III study.
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab
by Zacks Equity Research
The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Regeneron Pharmaceuticals, TJX Companies, Moderna and NVIDIA
Nasdaq Tops 15K for First Time: 5 Best Stocks in the ETF
by Sweta Killa
The tech-heavy Nasdaq Composite Index topped 15,000 for the first time ever driven by continued strength in tech stocks.
Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights
by Zacks Equity Research
Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
6 Must-Buy Corporate Giants As Major Indexes Hit Record High
by Nalak Das
We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.
Nasdaq Crosses 15K for 1st Time Ever; JWN, URBN Beat
by Mark Vickery
On the way to its fourth-straight up day in the market, the tech-heavy Nasdaq wound up surpassing 15K for its first time ever.
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.
Markets Bounce Back as Slow Summer Weeks Are Here
by Mark Vickery
Fewer than 90 companies are scheduled to release earnings this week, and at first glance none look to represent the S&P 500.
Wall Street Waits For The Fed's Big Event
by Zacks Equity Research
Wall Street Waits For The Fed's Big Event.
Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK
by Zacks Equity Research
Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.
Biotech ETFs to Benefit From Latest Booster Update
by Sweta Jaiswal, FRM
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
by Zacks Equity Research
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
Is Moderna (MRNA) COVID-19 Jab Heart Risk More Than Pfizer's?
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine is being probed for higher risk of heart inflammation compared to Pfizer's vaccine, per a Washington Post article.
Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Sutro's (STRO) investigational antibody-drug conjugate therapy, STRO-002, gets Fast Track designation from the FDA for advanced ovarian cancer.
US Set to Receive COVID-19 Vaccine Booster Dose Next Month
by Indrajit Bandyopadhyay
In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.
Biotech Stock Roundup: MRNA Vaccine Updates, Other Regulatory News & Collaborations
by Zacks Equity Research
Regulatory and pipeline updates from Moderna (MRNA) and CureVac (CVAC) among others were in focus in the biotech industry over the past week.
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
by Zacks Equity Research
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
Mei (MEIP) Begins Phase III Study for B-Cell Malignancies
by Zacks Equity Research
Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.
Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline
by Zacks Equity Research
Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.
Moderna (MRNA) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?